{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ichthyosis%2C+X-Linked",
    "query": {
      "condition": "Ichthyosis, X-Linked"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 47,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ichthyosis%2C+X-Linked&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T04:51:05.762Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04167579",
      "title": "STS & ACC Foundation's Transcutaneous Valve Therapy (TVT) Registry Foundation's Transcutaneous Valve Therapy (TVT) Registry",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Transcutaneous Valve Therapies"
      ],
      "interventions": [
        {
          "name": "Transcutaneous Valve Therapy",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Hoag Memorial Hospital Presbyterian",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5000,
      "start_date": "2019-05-20",
      "completion_date": "2025-05-20",
      "has_results": false,
      "last_update_posted_date": "2023-02-28",
      "last_synced_at": "2026-05-22T04:51:05.762Z",
      "location_count": 1,
      "location_summary": "Newport Beach, California",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04167579"
    },
    {
      "nct_id": "NCT06905132",
      "title": "Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "Hypofractionated Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2025-04-01",
      "completion_date": "2030-03-27",
      "has_results": false,
      "last_update_posted_date": "2026-03-30",
      "last_synced_at": "2026-05-22T04:51:05.762Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06905132"
    },
    {
      "nct_id": "NCT02451943",
      "title": "A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "Olaratumab",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 509,
      "start_date": "2015-09-14",
      "completion_date": "2024-06-27",
      "has_results": true,
      "last_update_posted_date": "2025-07-15",
      "last_synced_at": "2026-05-22T04:51:05.762Z",
      "location_count": 30,
      "location_summary": "Duarte, California • Los Angeles, California • Stanford, California + 20 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02451943"
    },
    {
      "nct_id": "NCT03345485",
      "title": "Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Small Cell Lung Cancer",
        "Soft Tissue Sarcoma",
        "Triple-negative Breast Cancer",
        "Ovarian Cancer",
        "Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "Tinostamustine 60mg/m2 over 30min",
          "type": "DRUG"
        },
        {
          "name": "Tinostamustine 80mg/m2 over 30min",
          "type": "DRUG"
        },
        {
          "name": "Tinostamustine 100mg/m2 over 30min",
          "type": "DRUG"
        },
        {
          "name": "Tinostamustine 60mg/m2 over 60min",
          "type": "DRUG"
        },
        {
          "name": "Tinostamustine 80mg/m2 over 60min",
          "type": "DRUG"
        },
        {
          "name": "Tinostamustine 100mg/m2 over 60min",
          "type": "DRUG"
        },
        {
          "name": "Tinostamustine 80mg/m2 over 80min",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mundipharma Research Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 71,
      "start_date": "2017-11-08",
      "completion_date": "2023-03-29",
      "has_results": true,
      "last_update_posted_date": "2024-10-21",
      "last_synced_at": "2026-05-22T04:51:05.762Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Palo Alto, California • Ann Arbor, Michigan + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03345485"
    },
    {
      "nct_id": "NCT05448820",
      "title": "YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Sarcoma",
        "Metastatic Sarcoma",
        "Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "YH001",
          "type": "DRUG"
        },
        {
          "name": "Envafolimab",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tracon Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2022-11-14",
      "completion_date": "2025-09",
      "has_results": false,
      "last_update_posted_date": "2023-09-21",
      "last_synced_at": "2026-05-22T04:51:05.762Z",
      "location_count": 6,
      "location_summary": "Santa Monica, California • Chicago, Illinois • New York, New York + 3 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05448820"
    },
    {
      "nct_id": "NCT02864082",
      "title": "A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Congenital Ichthyosis"
      ],
      "interventions": [
        {
          "name": "PAT-001, 0.1%",
          "type": "DRUG"
        },
        {
          "name": "PAT-001, 0.2%",
          "type": "DRUG"
        },
        {
          "name": "Vehicle for PAT-001 0.1%",
          "type": "DRUG"
        },
        {
          "name": "Vehicle for PAT-001 0.2%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Patagonia Pharmaceuticals, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2017-03-08",
      "completion_date": "2018-12-04",
      "has_results": true,
      "last_update_posted_date": "2021-09-29",
      "last_synced_at": "2026-05-22T04:51:05.762Z",
      "location_count": 5,
      "location_summary": "San Diego, California • New Haven, Connecticut • Chicago, Illinois + 2 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02864082"
    },
    {
      "nct_id": "NCT00755261",
      "title": "Phase II Study of Doxorubicin and Avastin® in Sarcoma.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sarcoma",
        "Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "Avastin",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2008-09",
      "completion_date": "2010-11",
      "has_results": true,
      "last_update_posted_date": "2015-05-08",
      "last_synced_at": "2026-05-22T04:51:05.762Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00755261"
    },
    {
      "nct_id": "NCT06748872",
      "title": "EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Epithelial Ovarian Cancer",
        "Gastro-esophageal Junction Cancer",
        "Soft Tissue Sarcoma (STS)",
        "Myxoid Liposarcoma",
        "Synovial Sarcoma"
      ],
      "interventions": [
        {
          "name": "Lymphodepletion",
          "type": "DRUG"
        },
        {
          "name": "TCR-T cells (MDG1015)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Medigene AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2025-07-01",
      "completion_date": "2042-08-01",
      "has_results": false,
      "last_update_posted_date": "2024-12-27",
      "last_synced_at": "2026-05-22T04:51:05.762Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06748872"
    },
    {
      "nct_id": "NCT03047369",
      "title": "The Myelin Disorders Biorepository Project",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Leukodystrophy",
        "White Matter Disease",
        "Leukoencephalopathies",
        "4H Syndrome",
        "Adrenoleukodystrophy",
        "AMN",
        "ALD",
        "ALD Gene Mutation",
        "ALD (Adrenoleukodystrophy)",
        "X-linked Adrenoleukodystrophy",
        "X-ALD",
        "Adrenomyeloneuropathy",
        "Aicardi Goutieres Syndrome",
        "AGS",
        "Alexander Disease",
        "Alexanders Leukodystrophy",
        "AxD",
        "ADLD",
        "Canavan Disease",
        "CTX",
        "Cerebrotendinous Xanthomatoses",
        "Krabbe Disease",
        "GALC Deficiency",
        "Globoid Leukodystrophy",
        "TUBB4A-Related Leukodystrophy",
        "H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum",
        "HBSL",
        "HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity",
        "LBSL",
        "Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder)",
        "Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation",
        "ALSP",
        "CSF1R Gene Mutation",
        "HCC - Hypomyelination and Congenital Cataract",
        "MLC1",
        "Megalencephalic Leukoencephalopathy With Subcortical Cysts",
        "MLD",
        "Metachromatic Leukodystrophy",
        "PMD",
        "Pelizaeus-Merzbacher Disease",
        "PLP1 Null Syndrome",
        "PLP1 Gene Duplication | Blood or Tissue | Mutations",
        "Pelizaeus Merzbacher Like Disease",
        "Peroxisomal Biogenesis Disorder",
        "Zellweger Syndrome",
        "Refsum Disease",
        "Salla Disease",
        "Sialic Storage Disease",
        "Sjögren",
        "Sjogren-Larsson Syndrome",
        "Van Der Knapp Disease",
        "Vanishing White Matter Disease",
        "Charcot-Marie-Tooth",
        "CMT",
        "Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency",
        "Allan-Herndon-Dudley Syndrome",
        "Cadasil",
        "Cockayne Syndrome",
        "Multiple Sulfatase Deficiency",
        "Gangliosidoses",
        "GM2 Gangliosidosis",
        "BPAN",
        "Labrune Syndrome",
        "LCC",
        "Mucopolysaccharidoses",
        "TBCK-Related Intellectual Disability Syndrome"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Children's Hospital of Philadelphia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 12000,
      "start_date": "2016-12-08",
      "completion_date": "2030-12-08",
      "has_results": false,
      "last_update_posted_date": "2025-10-23",
      "last_synced_at": "2026-05-22T04:51:05.762Z",
      "location_count": 23,
      "location_summary": "Los Angeles, California • Orange, California • Palo Alto, California + 18 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03047369"
    },
    {
      "nct_id": "NCT03126591",
      "title": "A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "Olaratumab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab (KEYTRUDA®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2017-07-03",
      "completion_date": "2023-02-21",
      "has_results": true,
      "last_update_posted_date": "2024-10-23",
      "last_synced_at": "2026-05-22T04:51:05.762Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • New York, New York • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03126591"
    }
  ]
}